Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Pre-Chemo Enzalutamide OS Benefit in mCRPC Reaches Nearly 30%
January 28th 2014, 3:34pm
Genitourinary Cancers Symposium (ASCO GU)
The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%
ASIs Demonstrate OS Benefit in mRCC, Appear Synergistic with Anti-VEGF Therapies
January 28th 2014, 3:03pm
Genitourinary Cancers Symposium (ASCO GU)
A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.
One in Five Cancer Trials End Too Early, but GU Studies Not More Likely
January 28th 2014, 3:03pm
Genitourinary Cancers Symposium (ASCO GU)
The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers.
RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'
January 20th 2014, 4:03pm
Gastrointestinal Cancers Symposium (ASCO GI)
Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.
Novel Targeted Agent Leads to Survival Benefit in HCC
January 20th 2014, 12:46pm
Gastrointestinal Cancers Symposium (ASCO GI)
Treatment with LY2157299 led to significant reductions in a prespecified biomarker that correlated with increased time to progression and overall survival in patients with advanced hepatocellular carcinoma.
Hedgehog Inhibitor Regimen Active in Advanced Pancreatic Cancer
January 20th 2014, 11:02am
Gastrointestinal Cancers Symposium (ASCO GI)
Add-on treatment with the hedgehog pathway inhibitor vismodegib demonstrated encouraging activity in patients with untreated metastatic pancreatic ductal adenocarcinoma.
Dr. John Marshall Provides Colorectal Cancer Updates
January 17th 2014, 12:38pm
Gastrointestinal Cancers Symposium (ASCO GI)
John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.
Dr. Fine on Capecitabine Plus Temozolomide for NETs
January 17th 2014, 8:42am
Gastrointestinal Cancers Symposium (ASCO GI)
Robert L. Fine, MD, from the Columbia University Medical Center, discusses the prospective phase II study of CAPTEM for patients with neuroendocrine tumors.
Dr. Smitha Krishnamurthi on the Phase III RAINBOW Trial
January 17th 2014, 6:38am
Gastrointestinal Cancers Symposium (ASCO GI)
Smitha Krishnamurthi, MD, discusses the results of the RAINBOW TRIAL
High Response Rates Observed With CAPTEM in Chemo-Resistant Neuroendocrine Tumors
January 14th 2014, 4:01pm
Gastrointestinal Cancers Symposium (ASCO GI)
Data from an interim analysis of an ongoing phase II study suggest that patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain "extraordinary responses" with capecitabine and temozolomide.
Neoadjuvant Capecitabine Considered a New Standard of Care in Rectal Cancer
January 14th 2014, 3:07pm
Gastrointestinal Cancers Symposium (ASCO GI)
Single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.
Ramucirumab Combination Improves Survival in Metastatic Gastric Cancer
January 14th 2014, 3:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
The combination of ramucirumab and paclitaxel resulted in a significant prolongation in survival and gains in quality of life when compared to paclitaxel alone for the second-line treatment of patients with metastatic gastric cancer.
Combined Vaccines Improve Survival in Metastatic Pancreatic Cancer
January 14th 2014, 3:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.
Second-Line mCRC Data Further Support RAS Testing Before Panitumumab Use
January 14th 2014, 2:59pm
Gastrointestinal Cancers Symposium (ASCO GI)
An analysis of phase III, second-line data has shown that RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer.
Dr. Garner Discusses the myRisk Hereditary Cancer Test
December 16th 2013, 1:51pm
San Antonio Breast Cancer Symposium
Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.
Postneoadjuvant Bisphosphonate Benefits in Breast Cancer Linked to Age, Menopausal Status
December 16th 2013, 12:04pm
San Antonio Breast Cancer Symposium
Postneoadjuvant bisphosphonate therapy in women with residual invasive disease following chemotherapy for primary breast cancer does not improve clinical outcomes, according to an interim analysis of a large phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
Dr. Esserman Discusses the I-SPY 2 Trial
December 16th 2013, 10:12am
San Antonio Breast Cancer Symposium
Laura J. Esserman, MD, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.
Dr. Brenner on the Link Between Breast Cancer and Obesity
December 13th 2013, 4:18pm
San Antonio Breast Cancer Symposium
Andrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.
Dr. Julie Gralow Discusses the SWOG S0500 Trial
December 13th 2013, 3:36pm
San Antonio Breast Cancer Symposium
Julie R. Gralow, MD, from the Seattle Cancer Care Alliance, discusses the SWOG S0500 trial, which evaluated different therapies for patients with metastatic breast cancer who had elevated circulating tumor cell levels.
Novel Trial Design Shows Early Value for Veliparib/Carboplatin in TNBC
December 13th 2013, 3:23pm
San Antonio Breast Cancer Symposium
The first results from the novel the I-SPY 2 trial show encouraging possibilities for a veliparib/carboplatin combination therapy in TNBC.